Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Young Adults

Overview

This study will evaluate the adaptations in skeletal muscle that occur in response to 10 weeks of weight training with or without peanut protein supplementation in untrained men and women ages 18-30

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Investigator, Outcomes Assessor)
  • Study Primary Completion Date: August 31, 2021

Detailed Description

This is a two-phase study using both novel and conventional methods to assess how PP supplementation affects muscle tissue in young adults who engage in resistance training. These two phases will be conducted as part of a 10-week randomized controlled trial in which men and women aged 18-30 years (n=40), will be stratified by gender and randomized to a resistance training intervention (whole body, two days per week) with PP powder (72g daily; n=10 males, n=10 females) provided during the intervention (immediate group, IG) or after the intervention (wait-list control, WLC, n=10 males, n=10 females). The aims of this study are to determine the acute (deuterium oxide tracer) and chronic (peripheral quantitative computed tomography) effects of PP during resistance training on skeletal muscle myofibrillar protein synthesis rates, changes in skeletal muscle size and quality, changes in whole and appendicular body composition (dual energy x-ray absorptiometry), changes in inflammatory markers and the fecal microbiome.

Interventions

  • Dietary Supplement: Peanut protein powder
    • Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
  • Behavioral: Full body resistance training
    • Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)

Arms, Groups and Cohorts

  • Experimental: Immediate Intervention Group
    • Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder (72g/day) will be provided for daily consumption during the study period
  • Active Comparator: Wait-list Control Group
    • Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder will be provided after the study period

Clinical Trial Outcome Measures

Primary Measures

  • Change in acute myofibrillar protein synthesis rates
    • Time Frame: 24 hours
    • Change in right leg vastus lateralis myofibrillar protein synthesis rates using the integrated deuterium oxide technique from biopsies immediately before and 24 hours after resistance exercise Change in right leg vastus lateralis myofibrillar protein synthesis rates using the integrated deuterium oxide technique from biopsies immediately before and 24 hours after resistance exercise
  • Change in mid-thigh skeletal muscle area and quality
    • Time Frame: 0-10 weeks
    • Peripheral quantitative computed tomography (pQCT) cross-sectional image of mid-right thigh assessed for overall muscle density (mg/cm^3)

Secondary Measures

  • Change in appendicular lean mass
    • Time Frame: 0-10 weeks
    • Change in lean mass (kg) of limbs as measured by dual energy x-ray absorptiometry (DXA)
  • Change in Type I and II Muscle Fiber Cross-Sectional Area
    • Time Frame: 0-10 weeks
    • Muscle biopsy immunofluorescent staining for determination of type I and type II muscle fiber cross sectional area (fCSA) as a cellular determinant of skeletal muscle hypertrophy
  • Change in leg extensor isokinetic dynamometry
    • Time Frame: 0-10 weeks
    • maximal isokinetic right leg extensions on an isokinetic dynamometer (BioDex)
  • Change in fecal microbiome composition
    • Time Frame: 0-10 weeks
    • alpha- and beta-diversity of 16S bacterial rDNA

Participating in This Clinical Trial

Inclusion Criteria

  • body mass index (body mass/height squared) less than 35 kg/m2 – resting blood pressure averaging less than 140/90 mmHg (with or without medication) Exclusion Criteria:

  • known peanut allergy – actively participating in resistance training for more than 2 days/week – any known overt cardiovascular or metabolic disease – metal implants that will interfere with x-ray procedures – medically necessary radiation exposure in the last six months (except dental x-ray) – any medical condition that would contradict participating in an exercise program, giving blood or donating a skeletal muscle biopsy (i.e. blood clotting disorder or taking blood thinners) – pregnant or trying to become pregnant

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 30 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Auburn University
  • Collaborator
    • Edward Via College of Osteopathic Medicine-Auburn
  • Provider of Information About this Clinical Study
    • Principal Investigator: Andrew Fruge, Assistant Professor – Auburn University
  • Overall Official(s)
    • Michael D Roberts, PhD, Principal Investigator, Associate Professor
  • Overall Contact(s)
    • Michael D Roberts, PhD, 3348441925, mdr0024@auburn.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.